Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced on October 18, 2011, the pricing of a significant $400 million offering of 1.875% convertible senior notes due October 1, 2016. This move aims to raise capital for the company's ongoing operations and development. The notes are exclusively offered to qualified institutional buyers under Rule 144A. Investors should note the convertible nature of these notes, which can be exchanged for cash and/or Regeneron's common stock, with an initial conversion price representing a substantial premium over the then-current market price. Furthermore, Regeneron has implemented a convertible note hedge and warrant strategy to mitigate potential dilution from the note conversion. The hedge transactions cover the shares underlying the notes, while the warrants are set at a strike price significantly above the stock's closing price on October 17, 2011. These financial instruments are designed to manage the impact of share price fluctuations and potential share issuances on the company's equity structure.
Key Highlights
- 1Regeneron priced a $400 million offering of 1.875% convertible senior notes due October 1, 2016.
- 2The offering is restricted to qualified institutional buyers under Rule 144A.
- 3The notes are convertible into cash and/or Regeneron common stock at the company's option.
- 4The initial conversion price of approximately $84.02 per share represents a 30% premium over the October 17, 2011 closing price of $64.63.
- 5Regeneron entered into convertible note hedge transactions to cover the shares underlying the notes, aimed at mitigating dilution.
- 6Warrant transactions were also executed with an initial strike price of approximately $103.41, representing a 60% premium over the stock's closing price.
- 7The company has the option to settle the warrant transactions in shares or cash.